Objectives The purpose of this study was to assess the efficacy and safety of dapagliflozin in
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …

Aims Obesity is common and associated with unique phenotypic features in heart failure
with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of …

Aims: To determine the projected benefits of dapagliflozin after an acute heart failure (HF)
event in Spain. Methods: A multicenter and prospective study that included subjects aged 50 …

Background N-terminal pro–B-type natriuretic peptide (NT-proBNP) is used for diagnostic
and prognostic evaluation in heart failure (HF). Previous clinical trials in heart failure with …

Importance Heart failure with improved ejection fraction (HFimpEF), defined as prior left
ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is …

Background The efficacy of dapagliflozin and empagliflozin in sodium-glucose cotransport-2
inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However, which …

Background The primary goals during acute heart failure (AHF) hospitalization are
decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics …

Importance In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
(DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and …

OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of …

Introduction Despite the progress made in the treatment of heart failure with reduced
ejection fraction (HFrEF) in recent years, the prognosis of the disease remains poor, with …